Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 429-437

  Vispo, Eugenia ^a   Barreiro, Pablo ^a   Pineda, Juan A ^b   Mira, José A ^b   Maida, Ivana ^a   Martín Carbonero, Luz ^a   Rodríguez Nóvoa, Sonia ^a   Santos, Ignacio ^c   López Cortes, Luis F ^d   Merino, Dolores ^e   Rivero, Antonio ^f   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REBOUND; RECOMMENDED DRUG DOSE; RELAPSE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIROLOGY; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; DRUG INTERACTION; GENETICS; MULTICENTER STUDY; RISK; RISK ASSESSMENT; SPAIN; TREATMENT FAILURE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DIDEOXYNUCLEOSIDES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; ODDS RATIO; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RIBAVIRIN; RISK ASSESSMENT; RNA, VIRAL; SPAIN; TREATMENT FAILURE; VIRAL LOAD;

EID: 43249088693     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Rockstroh J, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
2. Weber R, Sabin C, Friis-Moller N, et al. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
3. Chung R, Andersen J, Volberding P, et al. Peginterferon α-2a plus ribavirin versus interferon α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
4. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
5. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon α-2b vs standard interferon α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848.
6. Nuñez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23:972-982.
7. Mauss S, Valenti W, De Pamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21-F25.
8. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 2004; 9:133-138.
9. Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005; 40:47-52.
10. Henry D, Slim L, Lamarca A, Bowers P, Leitz G. Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection. AIDS Res Hum Retroviruses 2007; 23:1-9.
11. Garcia-Benayas T, Blanco F, Soriano V. Weight loss in HIV-infected patients. N Engl J Med 2002; 347:1287-1288.
12. Nuñez M, Mariño A, Miralles C, et al. Baseline hepatitis C virus RNA and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 45:439-444.
13. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 Suppl 1:17-24.
14. Morsica G, De Bona A, Foppa C, Sitia G, Finazzi R, Lazzarin A. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral therapy. AIDS 2000; 14:1656-1658.
15. Landau A, Batisse D, Piketty C, Jian R, Kazatchkine M. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000; 14:1857-1858.
16. Rodríguez-Torres M, Torriani F, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HIV-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother 2005; 49:3997-4008.
17. Margot N, Miller M. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Antivir Ther 2005; 10:343-348.
18. Ramanathan S, Cheng A, Mittan A, Ebrahimi R, Kearney B. Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. J Clin Pharmacol 2006; 46:559-566.
19. Sanchez-Conde M, Gil P, Sanchez-Somolinos M, Gonzalez-Lahoz J, Soriano V. Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin. HIV Clin Trials 2005; 6:278-280.
20. Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45:123-125.
21. Faletto M, Miller W, Garvey E, St Clair M, Daluge S, Good S. Unique intracellular activation of the potent anti-HIV agent 1592U89. Antimicrob Agents Chemother 1997; 41:1099-1107.
22. Wu J, Larson G, Walker H, Shim J, Hong Z. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5′ nucleotidase II: implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 2005; 49:2164-2171.
23. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.
24. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co infected patients. J Hepatol 2005; 42:615-624.
25. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003; 47:124-129.
26. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. Hepatology 1999; 30:1054-1058.
27. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38:128-133.
28. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41:275-279.
29. Ramos B, Nunez M, Rendón A, et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat 2007; 14:387-391.
30. Rendon A, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005; 39:401-405.
31. Nunez M, Camino N, Ramos B, et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 2005, 10:657-662.
32. Dixit N, Layden-Almer J, Layden T, Perelson A. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922-924.
33. Perelson A, Layden T. Ribavirin: is it a mutagen for hepatitis C virus? Gastroenterology 2007; 132:2050-2052.
34. Maag D, Castro C, Hong Z, Cameron C. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 276:46094-46098.
35. Herrmann E, Lee J, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358.
36. Graci J, Cameron C. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 2006; 16:37-48.
37. Pawlotsky J, Dahari H, Neumann A, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126:703-714.
38. Lau J, Tam R, Liang T, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35:1002-1009.
39. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky J. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 2007, 81:7732-7741.
40. Domingo E, Escarmis C, Lazaro E, Manrubia S. Quasispecies dynamics and RNA virus extinction. Virus Res 2005; 107:129-139.
41. Dahari H, Markatou M, Zeremski M, et al. HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007; 47:23-30.
42. Lutchman G, Danehower S, Song B, et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007; 132:1757-1766.
43. Henry S, Metselaar H, Lonsdale R, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporine A and interferon-alpha. Gastroenterology 2006; 131:1452-1462.
44. Weller S, Radomski K, Lou Y, Stein D. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with HIV-infected subjects. Antimicrob Agents Chemother 2000, 44:2052-2060.
45. Sun Y, Chung D, Chu Y, Jonsson C, Parker W. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5′-triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob Agents Chemother 2007; 51:84-88.